<- Go Home
Orexigen Therapeutics, Inc.
On May 31, 2019, Orexigen Therapeutics, Inc., went out of business as per its Chapter 11 liquidation filing under bankruptcy. Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California.
Market Cap
$100.1K
Volume
411.6K
Cash and Equivalents
$17.2M
EBITDA
-$91.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$46.8M
Profit Margin
52.80%
52 Week High
$0.16
52 Week Low
$0.00
Dividend
N/A
Price / Book Value
-0.00
Price / Earnings
-0.00
Price / Tangible Book Value
-0.00
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$100.0M
Return on Equity
145.60%
Return on Assets
-39.42
Cash and Short Term Investments
$17.2M
Debt
$237.3M
Equity
-$200.5M
Revenue
$88.6M
Unlevered FCF
-$83.1M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium